Another scientific publication followed the successful TT4CL project
Comparison in vitro susceptibility of clinical Leishmania isolates to miltefosine and oleylphosphocholine
OlPC exhibits superior in vitro antileishmanial activity compared to the only registerd oral drug for Cutaneous LeishmaniasisPublication
BREAKING NEWS
A potential new oral drug for leishmaniasis has successfully been tested in healthy humans.
English -
Nederlands -
Francais -
Español -
Deutsch
Press release July 15, 2019: Development of a new leishmaniasis drug wins EU funding
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of a Neglected Infectious (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps...
> Read More
Also available in:
Dutch -
German -
Farsi -
French